NCT07706179
Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer
StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Start date pushed from Oct 2026 to Nov 2026
- Notable Eligibility criteria expanded, about 10 words
- Start date: Sep 2026 to Oct 2026
- Secondary endpoints: details revised at 2 of 2 entries
- Minor Primary and study completion dates: Aug 2028 to Sep 2028
- Start date: Aug 2026 to Sep 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Clinical benefit defined as partial tumor response (PR)
Timeframe: 12 weeks
Clinical benefit defined as complete tumor response (CR)
Timeframe: 12 weeks
Clinical benefit defined as decline in circulating tumor DNA (ctDNA)
Timeframe: 12 weeks
Secondary (2)
Evaluate safety of adding alisertib to usual care by assessing adverse events
BRD8 signature expression
Arms and interventions
Alisertib plus standard of careExperimental
Participants receive alisertib in addition to usual care
Drugs: Alisertib
Sites
1 site in 1 country
- University of Wisconsin Carbone Cancer CenterMadison, Wisconsin, United States